Continue monitoring. No immediate action required.
Note: SpO2 monitoring is supplementary screening and cannot substitute for pulmonary function testing (spirometry). Normal SpO2 does not exclude early-stage BOS (bronchiolitis obliterans syndrome).
Slope: -0.00402%/day (-0.121%/month). 95% CI: [-0.01075, 0.00270]. p=0.2360.
Prediction:
| Time Horizon | Predicted SpO2 | 95% PI |
|---|---|---|
| 30d | 95.8% | [94.6, 97.0]% |
| 60d | 95.7% | [94.4, 97.0]% |
| 90d | 95.6% | [94.2, 97.0]% |
Concern Level: LOW
Absolute threshold (<94%): 0 nights (0.0%)
Relative threshold (<95.56%, baseline-2SD): 9 nights (15.3%)
Frequency trend: First half: 0.0% vs second half: 0.0% - Stable
Overall SD: 0.556% | CV: 0.579%
Night-to-night difference SD: 0.664%
First half SD: 0.504% vs second half: 0.604% - Stable
Pearson r: 0.0127 (p=0.920774)
Spearman rho: -0.0226 (p=0.859292)
Status: DECOUPLED (positive - abnormal)
Interpretation: Positive SpO2-HR coupling suggests loss of the expected compensatory inverse response.
Normal: Inverse relationship (SpO2 down -> HR up, compensatory). Decoupling (positive or zero correlation) = autonomic dysfunction or respiratory failure.
DLCO Measurements:
| Date | DLCO% | Context | Concurrent SpO2 |
|---|---|---|---|
| 2024-03-21 | 71% | Baseline post-HSCT | No data |
| 2025-03-20 | 89% | Improvement | No data |
| 2025-12-17 | 67% | Concerning decline | No data |
DLCO Trajectory: 71% (Baseline post-HSCT) -> 89% (Improvement) -> 67% (Concerning decline)
SpO2 monitoring started after the last DLCO measurement. Direct correlation not possible, but trend direction is consistent with DLCO decline.
Mean BDI: 5.19 events/hour (status: MILD ELEVATION)
Elevated nights (>=5): 32 of 58 (55.2%)
BDI trend: slope=0.005/day (p=0.805747)
Pearson r: 0.0297 (p=0.823278)
Interpretation: Weak coupling: SpO2 relatively independent of temperature
Composite Score: 17/100 - LOW
| Component | Score | Weight | Contribution |
|---|---|---|---|
| SpO2 Trend | 10/100 | 30% | 3.0 |
| SpO2 Variability | 8/100 | 20% | 1.6 |
| Desaturation Frequency | 0/100 | 20% | 0.0 |
| Breathing Disturbance Index (BDI) | 31/100 | 15% | 4.6 |
| HR Decoupling | 51/100 | 15% | 7.7 |
Pre-ruxolitinib (55 nights): 96.079% (SD: 0.569%)
Post-ruxolitinib (4 nights): 96.003%
Status: No statistically significant change after ruxolitinib (yet)
Mann-Whitney U: 121.5 (p=0.740137), effect size (rbc)=-0.1045